UK govt launches review of business-university growth opportunities, to be led by GlaxoSmithKline CEO

10 April 2013

A review to boost growth opportunities for universities and businesses in the UK has been launched by Universities and Science Minister David Willetts. The independent review will be led by Sir Andrew Witty, chief executive of UK pharma giant GlaxoSmithKline (LSE: GSK), who is also Chancellor of the University of Nottingham. It will offer practical steps for building relationships between universities, local businesses and local business bodies, including Local Enterprise Partnerships (LEPs).

Announcing the project, Minister Willetts said: “A strong relationship between businesses and universities can provide real growth opportunities in local areas. By forging links and sharing best practice, an efficient and practical partnership will help to boost the economy, benefiting both businesses and institutions. It is critical to the government’s industrial strategy that universities play a full role in driving growth at a local level and then taking it on to a national and global scale.”

The review will take into account recent developments including the government’s response to Lord Heseltine’s report “No Stone Unturned,” the industrial strategy and the approach to European Union structural funds, including “smart specialization.”

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology